Last reviewed · How we verify
PROTHERACYTES
At a glance
| Generic name | PROTHERACYTES |
|---|---|
| Sponsor | CellProthera |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- EXCELLENT (EXpanded CELL ENdocardiac Transplantation) (PHASE2)
- A Multicentre Observational Study to Assess Long-term Outcome of Participants in the EXCELLENT Clinical Trial
- SINGaporean Program Performed With an eXPANsion Medical Device (SingXpand) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PROTHERACYTES CI brief — competitive landscape report
- PROTHERACYTES updates RSS · CI watch RSS
- CellProthera portfolio CI